CAREDX (CDNA)

EARNINGS RELEASE THURSDAY - APRIL 30 (AMC)

Trade Assist May Not Be Available For All Jump Trades (See Trade Plan

Ticker delayed 20 minutes

JUMP BACK

JUMP REPORT

Avg Daily Volume: 795,234    Market Cap: 812.56M
Sector: Services    Short Interest: 14.11

EARNINGS EXPECTATIONS:  

     THIS QTR:   EPS:     .03/share     REV:  37.99/M
___________________________________________________________
     LAST QTR:  EPS:     .01/share     ACTUAL:   .04/share  (BEAT)
____________________________________________________________
     NEXT QTR:  EPS:     .01/share      REV:  38.9/M
______________________________________________________
     FULL YR:     EPS:     .13/share    REV: 164.68/M
______________________________________________________

*These are the base metrics we will be watching against the actual release numbers
__________________________________________________________________

BEAT/MISS RECORD:  –% OF THE TIME THEY BEAT ESTIMATES

PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -13.59, 9.11, 12.55

EXPECTED JUMP MOVE:  10-15%

——–

*** With market volatility at extremes during the coronavirus pandemic there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading. 

Links To Latest News and Headlines

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare’s (THC) third-quarter earnings gain from the Ambulatory segment and lower expenses.

21 Oct, 2020 @ 11:00 by Yahoo! Finance

General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meetingSOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a leading presence with AlloSure education at the American Society of Nephrology (ASN) annual conference from October 22 – 25, 2020. The ASN annual conference, otherwise known as Kidney Week, will be run virtually this year. Eleven clinical abstracts on AlloSure have been selected for presentation during the poster and publication sessions of the conference, indicating that general nephrologists have a growing interest in surveillance tools for transplant patient management. CareDx also provided a grant for the educational symposium Diagnostic Controversies in Transplantation: Of Biomarkers and Biopsies.CareDx will host an Exhibitor Spotlight titled AlloSure as a Tool for Surveillance of Renal Transplant Patients: Real-World Evidence and Clinical Utility. During the spotlight session, five nephrologists will discuss their experiences with AlloSure and how it has benefitted their practice and their patients. The speakers and topics will be: * Dr. Vasil Peev, Rush University: Clinical Utility of Kidney Transplant Surveillance with AlloSure * Dr. Sanjiv Anand, Intermountain Medical Center: Baseline Characteristics and Relative Change Value of AlloSure * Dr. Tarek Alhamad, Barnes-Jewish Hospital: AlloSure as a Predictor of Clinical Outcomes * Dr. Nicole Ali, NYU Langone Health: COVID-19 and Renal Transplantation: The NYU Experience * Dr. Adit Mahale, Metrolina Nephrology Associates: AlloSure Experience in the Community “I am looking forward to presenting real-world AlloSure surveillance data across 1000 patients from multiple centers. It is really positive to see confirmation of the validation data in a cohort of real-world transplant patients, as well as the associations with meaningful clinical outcomes,” said Dr. Tarek Alhamad, Associate Professor and Medical Director of Transplant Nephrology at Washington University School of Medicine.“ASN is a tremendous opportunity for the nephrology community to share their experiences and to talk about best practices in kidney care for patients. This conference allows us to update the general nephrologists on the work that CareDx is doing to further clinical practice in transplant patient management,” said Peter Maag, CEO of CareDx.About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com

CMS believes AlloMap reimbursement process is clinically appropriate for heart transplant patientsSOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today that the Centers for Medicare and Medicaid Services (CMS) recently issued a memo recommending continued coverage of AlloMap through local Medicare Administrative Contractors (MACs). AlloMap is widely adopted by physician providers in over 90% of transplant centers across the US, has been the standard of care and incorporated into guidelines by the International Society for Heart and Lung Transplantation (ISHLT) since 2010, and is covered by a CPT code which is reimbursed by Noridian, the local MAC in California.The recently issued CMS memo was in response to a request made by a pathologist in January 2013 to make a national coverage determination to non-cover AlloMap. The CMS memo acknowledges that since 2013 there have been multiple studies that have demonstrated the clinical utility of AlloMap, and concludes that continuing the current AlloMap reimbursement process by MACs is clinically appropriate and in the best interests of beneficiaries.   “AlloMap has stood the test the time and is now cemented as the standard of care, being part of ISHLT guidelines since 2010. We continue to generate new insights with AlloMap with a strong growing evidence base, and it is positive to see CMS evaluate this evidence and continue to support use of AlloMap,” said Jeffrey Teuteberg, MD, Stanford.“CareDx is appreciative of the thorough evidence reviews performed by CMS, which reaffirm the clinical utility of AlloMap, and supports the CMS proposal to continue the current reimbursement process through MACs. Our dedication to patients continues to provide relevant testing services that are well supported by clinical data,” said Reg Seeto, President and Chief Business Officer, CareDx.About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com

Virtual events to highlight newest innovation and solutions for HLA labs during ASHI conferenceSOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it will share the latest data on CareDx products for HLA laboratories at the 46th annual meeting of The American Society for Histocompatibility and Immunogenetics (ASHI). ASHI will be hosted virtually from October 19th – 21st 2020.At ASHI 2020, CareDx will host a virtual symposium, a virtual happy hour, and several meet-the-expert sessions. The symposium titled “Changing the Paradigm of HLA Typing: More HLA, More than HLA” will be held on Tuesday, Oct 20th from 2 PM – 3 PM EDT. The program will highlight the experience from Dr. Rajalingam Raja, Ph.D., FRCPath., D(ABHI). He is the Director of the Immunogenetics and Transplantation Laboratory at UCSF and will share his experience using AlloSeq Tx17 as their primary HLA typing solution.Additionally, there will be one oral talk on AlloSeq Tx 17 and nine posters on CareDx offerings presented during ASHI:Presentation: Monday, October 19th, 2020, 3:00 – 4:30 PM EDT * Reduced PCR-induced errors from a hybrid capture-based NGS assay for HLA typing – Nicholas Brown, PhD, University of PennsylvaniaPoster Session: Tuesday, October 20th, 2020, 5:30 – 6:30 PM EDT * AlloSeq Tx Hybrid Capture Technique allows successful typing with poorly performing registry samples and difficult samples where PCR-based methodologies fail * Beyond HLA-NGS AlloSeq TX 8 novel hybrid capture approach for high throughput volunteer donor typing with expandable gene content including ABO * 96 Sample throughput HLA typing following targeted gene enrichment by hybrid capture * Quantitative application of hybrid capture for HLA typing: Confirmation of hemizygosity and potential for detection of LOH * Genetic risk factors in solid organ transplantation: Beyond classical human leukocyte antigen * Description of 14 new HLA-J alleles reveals four distinct lineages * The HLA-F, -G, -H haplotype on the 8.1 ancestral haplotype differs from non-8.1 haplotypes with a *01:01:01:01: Implications for disease association studies and unrelated hematopoietic stem cell transplant * 35 UNIQUE HLA-f, -G, -H Haplotypes and their relationships to HLA-A: HLA-A is insufficient as a marker for genomic matching in unrelated HSCT * AlloSeq HCT, an accurate, reproducible and sensitive NGS-based solution for chimerism monitoring“These unprecedented times shine a light on how important our work is within the HLA community,” said Maria P. Bettinotti, PhD, Assistant Professor of Medicine and Director, Immunogenetics Laboratory, Johns Hopkins School of Medicine. “I am glad that CareDx is leveraging this Virtual ASHI platform and engaging this community while offering collaborative and innovative talks during this conference.”“Each year ASHI allows us to update the HLA laboratory community on the work that CareDx is doing in the field of immunogenetics and transplant immunology,” said Peter Maag, CEO of CareDx. “This year, we will have some exciting presentations for the pre- and post-transplant audiences along with multiple opportunities for physicians to learn from one another and get valuable updates regarding best practices in patient care.”About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com

StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.

“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up  Looking forward to having you on-board ASAP”

There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory. 

NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.